Wang Yu-Kun, Zhu Rong-Wei, Gao Zhi-Peng, Tao Yi
Thyroid and Breast Surgery Department, the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China.
Clinical Integration of Traditional Chinese and Western Medicine, Guangxi University of Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China.
World J Clin Cases. 2024 Jul 16;12(20):4074-4081. doi: 10.12998/wjcc.v12.i20.4074.
Breast cancer (BC) is the second leading cause of tumor-related mortality after lung cancer. Chemotherapy resistance remains a major challenge to progress in BC treatment, warranting further exploration of feasible and effective alternative therapies.
To analyzed the quality of life (QoL) and survival of patients with BC treated with integrated traditional Chinese and Western medicine (TCM-WM).
This study included 226 patients with BC admitted to the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine between February 2018 and February 2023, including 100 who received conventional Western medicine treatment (control group) and 126 who received TCM-WM treatment (research group). The total effective rate, side effects (alopecia, nausea and vomiting, hepatorenal toxicity, and myelosuppression), QoL assessed using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30), 1-year overall survival (OS), recurrence and metastasis rates, and serum inflammatory factors [interleukin (IL)-6, IL-10, and tumor necrosis factor alpha] were comparatively analyzed.
The research group showed statistically better overall efficacy, EORTC QoL-C30 scores, and 1-year OS than the control group, with markedly lower side effects and 1-year recurrence and metastasis rates. Moreover, the posttreatment levels of serum inflammatory in the research group were significantly lower than the baseline and those in the control group.
Overall, TCM-WM demonstrated significantly improved therapeutic efficacy while ensuring drug safety in BC, which not only improved patients' QoL and prolonged survival, but also significantly inhibited the inflammatory response.
乳腺癌（BC）是继肺癌之后肿瘤相关死亡的第二大主要原因。化疗耐药仍然是乳腺癌治疗进展的主要挑战，需要进一步探索可行且有效的替代疗法。
分析中西医结合治疗乳腺癌患者的生活质量（QoL）和生存率。
本研究纳入了2018年2月至2023年2月期间广西中医药大学第一附属医院收治的226例乳腺癌患者，其中100例接受传统西医治疗（对照组），126例接受中西医结合治疗（研究组）。比较分析总有效率、副作用（脱发、恶心呕吐、肝肾毒性和骨髓抑制）、使用欧洲癌症研究与治疗组织核心生活质量问卷（EORTC QLQ-C30）评估的生活质量、1年总生存率（OS）、复发和转移率以及血清炎症因子[白细胞介素（IL）-6、IL-10和肿瘤坏死因子α]。
研究组在总体疗效、EORTC QoL-C30评分和1年总生存率方面在统计学上优于对照组，副作用以及1年复发和转移率明显更低。此外，研究组治疗后血清炎症水平显著低于基线水平和对照组。
总体而言，中西医结合在确保乳腺癌药物安全性的同时显著提高了治疗效果，不仅改善了患者的生活质量并延长了生存期，还显著抑制了炎症反应。
